Calycosin-7-O-β-D-glucoside attenuates palmitate-induced lipid accumulation in hepatocytes through AMPK activation

Eur J Pharmacol. 2022 Jun 15:925:174988. doi: 10.1016/j.ejphar.2022.174988. Epub 2022 Apr 29.

Abstract

Calycosin-7-O-β-D-glucoside (CG) is the major component of Astragali Radix (AR), a traditional Chinese drug. As reported, CG could attenuate cerebral ischemia/reperfusion injury, protect blood-brain barrier integrity, and ameliorate myocardial infarction. To date, whether CG has a protective effect on metabolic diseases remains to be elucidated. In the present study, CG could attenuate palmitate-induced lipid accumulation in hepatocytes in a dose-dependent manner, with down-regulation of lipogenesis related genes expression and up-regulation of lipids β-oxidation related genes expression. CG could decrease the triglyceride (TG) content from 0.30 mmol/g protein to 0.21 mmol/g protein and reduce the total cholesterol (TC) content from 0.39 mmol/g protein to 0.26 mmol/g protein. Moreover, CG stimulated the phosphorylation of AMP-activated protein kinase (AMPK), and the protective effect of CG on hepatocytes was partially reversed both by the inhibitor of AMPK signaling pathway and overexpression of AMPK-DN. Our findings revealed that CG could ameliorate palmitate-induced lipids accumulation in hepatocytes via AMPK activation and it may be a promising therapeutic medicine for hepatic steatosis.

Keywords: AMPK; Calycosin-7-O-β-D-glucoside; Hepatic steatosis; Hepatocyte; Lipogenesis.

MeSH terms

  • AMP-Activated Protein Kinases* / metabolism
  • Glucosides / pharmacology
  • Hepatocytes
  • Isoflavones
  • Palmitates* / pharmacology

Substances

  • Glucosides
  • Isoflavones
  • Palmitates
  • calycosin-7-O-beta-D-glucoside
  • AMP-Activated Protein Kinases